Author/Authors :
HUANG, Shuwen Department of Pediatrics - The People’s Hospital of Zhangqiu Area - Jinan, China , LIU, Lin Department of Pharmacy - Qingdao Women and Children’s Hospital - Qingdao, China , Guanglei QIAN Department of Pediatrics - The People’s Hospital of Zhangqiu Area, Jinan, China , LIU, Wenxue Department of Pediatrics - The People’s Hospital of Zhangqiu Area, Jinan, China , WANG, Jialiang Department of Radiology - The People’s Hospital of Zhangqiu Area, Jinan, China , Ming LI, Mingli Department of Pharmacy - The Affiliated Hospital of Shandong University of TCM - Shandong Provincial Hospital of Traditional Chi-nese Medicine, Jinan, China , YANG, Guang Department of Pediatrics - Yantaishan Hospital, Yantai, China
Abstract :
Background: To explore the effect of different doses of Gamma Globulin (GG) on the condition of children with Hemolytic Disease of Newborn (HDN) and the influence of immune factors in serum.
Methods: Overall, 180 infants with hemolytic disease of newborn in the People’s Hospital of Zhangqiu Area, Jinan, China from April 2016 to August 2018 were divided into group A (88 cases) and group B (92 cases). Group A was given intravenous low-dose GG on the basis of phototherapy, and group B was given intravenous high-dose GG on the basis of phototherapy. The level of serum total bilirubin of the infants, the levels of CD3+, CD4+, CD8+, of the infants, the time of jaundice disappearance and the length of hospital stay, hemoglobin and reticulocyte levels were recorded before treatment and after treatment. The number and condition of adverse reactions were recorded.
Results: After treatment, the levels of TBiL, hemoglobin and reticulocyte, the time of jaundice disappearance and hospital stay in group B were significantly lower than those in group A. The level of immune cells in group B was significantly higher than that in group A after 7 days of treatment, and the levels of IgA / IgG / IgM in group B were significantly higher than those in group A after 28 days of treatment.
Conclusion: Intravenous high-dose GG has a better effect on the condition of neonatal hemolytic disease patients, and more effectively improve the immune function of children.
